452 related articles for article (PubMed ID: 21094909)
1. Incretin-based therapy and type 2 diabetes.
Hare KJ; Knop FK
Vitam Horm; 2010; 84():389-413. PubMed ID: 21094909
[TBL] [Abstract][Full Text] [Related]
2. Incretin-based therapy of type 2 diabetes mellitus.
Knop FK; Vilsbøll T; Holst JJ
Curr Protein Pept Sci; 2009 Feb; 10(1):46-55. PubMed ID: 19275672
[TBL] [Abstract][Full Text] [Related]
3. The spectrum of antidiabetic actions of GLP-1 in patients with diabetes.
Vilsbøll T; Holst JJ; Knop FK
Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):453-62. PubMed ID: 19748063
[TBL] [Abstract][Full Text] [Related]
4. Replacing SUs with incretin-based therapies for type 2 diabetes mellitus: challenges and feasibility.
Knop FK; Holst JJ; Vilsbøll T
IDrugs; 2008 Jul; 11(7):497-501. PubMed ID: 18600596
[TBL] [Abstract][Full Text] [Related]
5. Therapies for the treatment of type 2 diabetes mellitus based on incretin action.
Gallwitz B
Minerva Endocrinol; 2006 Jun; 31(2):133-47. PubMed ID: 16682937
[TBL] [Abstract][Full Text] [Related]
6. Incretin-based therapies: mimetics versus protease inhibitors.
Brubaker PL
Trends Endocrinol Metab; 2007 Aug; 18(6):240-5. PubMed ID: 17629492
[TBL] [Abstract][Full Text] [Related]
7. Incretin mimetics and dipeptidyl peptidase-IV inhibitors: potential new therapies for type 2 diabetes mellitus.
Triplitt C; Wright A; Chiquette E
Pharmacotherapy; 2006 Mar; 26(3):360-74. PubMed ID: 16503716
[TBL] [Abstract][Full Text] [Related]
8. The biology of incretin hormones.
Drucker DJ
Cell Metab; 2006 Mar; 3(3):153-65. PubMed ID: 16517403
[TBL] [Abstract][Full Text] [Related]
9. Potential new approaches to modifying intestinal GLP-1 secretion in patients with type 2 diabetes mellitus: focus on bile acid sequestrants.
Holst JJ; McGill MA
Clin Drug Investig; 2012 Jan; 32(1):1-14. PubMed ID: 21958333
[TBL] [Abstract][Full Text] [Related]
10. [Analogs of glucagon-like peptide-1 (GLP-1): an old concept as a new treatment of patients with diabetes mellitus type 2].
Diamant M; Bunck MC; Heine RJ
Ned Tijdschr Geneeskd; 2004 Sep; 148(39):1912-7. PubMed ID: 15495988
[TBL] [Abstract][Full Text] [Related]
11. Incretin hormone secretion over the day.
Ahrén B; Carr RD; Deacon CF
Vitam Horm; 2010; 84():203-20. PubMed ID: 21094901
[TBL] [Abstract][Full Text] [Related]
12. The incretin system and its role in type 2 diabetes mellitus.
Holst JJ; Vilsbøll T; Deacon CF
Mol Cell Endocrinol; 2009 Jan; 297(1-2):127-36. PubMed ID: 18786605
[TBL] [Abstract][Full Text] [Related]
13. Incretin based therapies for type 2 diabetes mellitus.
Ghosh S; Collier A; Elhadd T; Malik I
J Indian Med Assoc; 2008 Jun; 106(6):373-4, 383, 388. PubMed ID: 18839649
[TBL] [Abstract][Full Text] [Related]
14. Long-acting GLP-1 analogs for the treatment of type 2 diabetes mellitus.
Vilsbøll T; Knop FK
BioDrugs; 2008; 22(4):251-7. PubMed ID: 18611067
[TBL] [Abstract][Full Text] [Related]
15. Dipeptidyl peptidase-IV inhibitors can restore glucose homeostasis in type 2 diabetics via incretin enhancement.
Mest HJ
Curr Opin Investig Drugs; 2006 Apr; 7(4):338-43. PubMed ID: 16625820
[TBL] [Abstract][Full Text] [Related]
16. The entero-insular axis in type 2 diabetes--incretins as therapeutic agents.
Creutzfeldt W
Exp Clin Endocrinol Diabetes; 2001; 109 Suppl 2():S288-303. PubMed ID: 11460578
[TBL] [Abstract][Full Text] [Related]
17. Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus.
Freeman JS
Cleve Clin J Med; 2009 Dec; 76 Suppl 5():S12-9. PubMed ID: 19952298
[TBL] [Abstract][Full Text] [Related]
18. GLP-1 agonists and dipeptidyl-peptidase IV inhibitors.
Gallwitz B
Handb Exp Pharmacol; 2011; (203):53-74. PubMed ID: 21484567
[TBL] [Abstract][Full Text] [Related]
19. New physiological effects of the incretin hormones GLP-1 and GIP.
Asmar M
Dan Med Bull; 2011 Feb; 58(2):B4248. PubMed ID: 21299928
[TBL] [Abstract][Full Text] [Related]
20. Newly approved and promising antidiabetic agents.
Combettes M; Kargar C
Therapie; 2007; 62(4):293-310. PubMed ID: 17983555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
